Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ARCM NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCMArrow Reserve Capital Management ETF$100.35+0.0%$100.33$99.99▼$101.74$46.15M0.01723 shs193 shsKODKodiak Sciences$4.70-2.4%$3.85$1.92▼$11.60$248.50M2.28349,824 shs112,875 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCMArrow Reserve Capital Management ETF+0.01%+0.08%0.00%-0.04%-0.06%KODKodiak Sciences-6.96%+23.33%+23.97%+103.81%+62.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCMArrow Reserve Capital Management ETFN/AN/AN/AN/AN/AN/AN/AN/AKODKodiak Sciences4.0205 of 5 stars3.02.00.04.63.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCMArrow Reserve Capital Management ETF 0.00N/AN/AN/AKODKodiak Sciences 2.00Hold$9.0091.69% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCMArrow Reserve Capital Management ETFN/AN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCMArrow Reserve Capital Management ETFN/AN/A0.00∞N/AN/AN/AN/AN/AKODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)Latest ARCM, RBW, MKA, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KODKodiak Sciences-$1.01N/AN/AN/AN/AN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCMArrow Reserve Capital Management ETF$4.634.61%N/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCMArrow Reserve Capital Management ETFN/AN/AN/AKODKodiak SciencesN/A4.624.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCMArrow Reserve Capital Management ETFN/AKODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipARCMArrow Reserve Capital Management ETFN/AKODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCMArrow Reserve Capital Management ETFN/A460,000N/ANot OptionableKODKodiak Sciences9052.76 million28.55 millionOptionableARCM, RBW, MKA, and KOD HeadlinesRecent News About These CompaniesEnduring the heat of CaliforniaJuly 15 at 2:27 PM | kodiakdailymirror.comKPenny Stocks To Watch In July 2025July 11, 2025 | finance.yahoo.comNASDAQ:KOD Financials | Kodiak Sciences Inc - Investing.comJuly 10, 2025 | investing.comKodiak Sciences to Host Investor R&D Day on July 16, 2025July 10, 2025 | prnewswire.comPeapod Lane Capital LLC Trims Position in Kodiak Sciences Inc. (NASDAQ:KOD)July 10, 2025 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Stock Price Up 5.1% - Time to Buy?July 9, 2025 | marketbeat.comKodiak Sciences Inc. Advanced Charts | KOD | Barron'sJuly 9, 2025 | barrons.comKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society - MorningstarJune 27, 2025 | morningstar.comMKodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)June 27, 2025 | ophthalmologytimes.comOKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation SocietyJune 25, 2025 | prnewswire.comKodiak Sciences Inc. (NASDAQ:KOD) Short Interest UpdateJune 17, 2025 | marketbeat.comBank of America Corp DE Has $169,000 Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)June 16, 2025 | marketbeat.comWhy Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?June 13, 2025 | zacks.comTrump’s cuts to fisheries science have industry and conservation groups sounding alarmJune 11, 2025 | kucb.orgKAlaska Aerospace, UAF to partner on new space venturesJune 11, 2025 | kodiakdailymirror.comKRetinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 5, 2025 | theglobeandmail.comKodiak Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | prnewswire.comKodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroadsMay 29, 2025 | investing.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deKodiak Sciences Shares Drop After Wider-Than-Expected 1Q LossMay 15, 2025 | marketwatch.comKodiak Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCM, RBW, MKA, and KOD Company DescriptionsArrow Reserve Capital Management ETF BATS:ARCM$100.35 +0.04 (+0.04%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Arrow Reserve Capital Management ETF (ARCM) is an exchange-traded fund that mostly invests in investment grade fixed income. The fund is an actively managed fund that seeks to preserve capital and maximize income potential by investing in investment-grade, short-term debt securities. ARCM was launched on Mar 31, 2017 and is managed by ArrowShares.Kodiak Sciences NASDAQ:KOD$4.70 -0.12 (-2.39%) As of 02:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
